Metabolome and metaboproteome remodeling in nuclear reprogramming

Cell Cycle

Volumn 12, Issue 15, 2013, Pages 2355-2365

  Folmes, Clifford D L ^a   Kent Arrell, D ^a   Zlatkovic Lindor, Jelena ^a   Martinez Fernandez, Almudena ^a   Perez Terzic, Carmen ^a   Nelson, Timothy J ^a   Terzic, Andre ^a  

^a MAYO CLINIC   (United States)

Author keywords

Energy metabolism; Glycolysis; IPS cells; Mitochondria; Network biology; Oxidative phosphorylation; Proteomics; Regenerative medicine; Systems biology

Indexed keywords

ARGININE; PROLINE; PROTEOME; PURINE; RIBONUCLEOTIDE;

ACIDIFICATION; AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CELL FATE; CONTROLLED STUDY; EMBRYO; GLYCOLYSIS; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PHOSPHATE METABOLISM; PROTEOMICS; REDUCTION; SYSTEM ANALYSIS; SYSTEMS BIOLOGY; TURNOVER TIME;

IPS;

ENERGY METABOLISM; GLYCOLYSIS; IPS CELLS; MITOCHONDRIA; NETWORK BIOLOGY; OXIDATIVE PHOSPHORYLATION; PROTEOMICS; REGENERATIVE MEDICINE; SYSTEMS BIOLOGY;

ANIMALS; CELLS, CULTURED; FIBROBLASTS; GENE ONTOLOGY; GENE REGULATORY NETWORKS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; METABOLOME; MICE; MITOCHONDRIA; NUCLEAR REPROGRAMMING; PROTEIN INTERACTION MAPS; PROTEOME;

EID: 84881498096     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25509     Document Type: Article

References (69)

1. Cherry AB, Daley GQ. Reprogramming cellular identity for regenerative medicine. Cell 2012; 148:1110-22; PMID:22424223; http://dx.doi.org/10.1016/j. cell.2012.02.031
2. Sancho-Martinez I, Li M, Izpisua Belmonte JC. Disease correction the iPSC way: advances in iPSCbased therapy. Clin Pharmacol Ther 2011; 89:746-9; PMID:21389982; http://dx.doi.org/10.1038/clpt.2010.341
3. Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. Clin Pharmacol Ther 2011; 89:648-50; PMID:21512525; http://dx.doi.org/10.1038/clpt.2010.304
4. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 2011; 89:655-61; PMID:21430656; http://dx.doi. org/10.1038/clpt.2011.38
5. Ellis J, Bhatia M. iPSC technology: platform for drug discovery. Point. Clin Pharmacol Ther 2011; 89:639-41; PMID:21512521; http://dx.doi.org/10.1038/ clpt.2011.22
6. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 2009; 120:408-16; PMID:19620500; http://dx.doi.org/10.1161/CIRCULATIONAHA.109.865154
7. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920-3; PMID:18063756; http://dx.doi.org/10. 1126/science.1152092
8. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008; 105:5856-61; PMID:18391196; http://dx.doi.org/10.1073/pnas.0801677105
9. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009; 106:808-13; PMID:19139414; http://dx.doi.org/10.1073/pnas. 0812090106
10. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3:595-605; PMID:19041776; http://dx.doi.org/10.1016/j. stem.2008.11.008
11. Ellis J, Bruneau BG, Keller G, Lemischka IR, Nagy A, Rossant J, et al. Alternative induced pluripotent stem cell characterization criteria for in vitro applications. Cell Stem Cell 2009; 4:198-9, author reply 202; PMID:19265656; http://dx.doi.org/10.1016/j. stem.2009.02.010
12. Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 2009; 4:200-1, author reply 202; PMID:19265657; http://dx.doi.org/10.1016/ j. stem.2009.02.009
13. Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol 2010; 7:700-10; PMID:20956984
14. Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol 2009; 220:21-9; PMID:19326392; http://dx.doi.org/10.1002/jcp.21681
15. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, et al. Somatic oxidative bioenergetics transitions into pluripotency- dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10.1016/j.cmet.2011.06.011
16. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22:168-77; PMID:22064701; http://dx.doi. org/10.1038/cr.2011.177
17. Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA 4th, Ramalho-Santos J, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 2011; 6:e20914; PMID:21698063; http://dx.doi. org/10.1371/journal.pone.0020914
18. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 2010; 28:721-33; PMID:20201066; http://dx.doi.org/10.1002/stem.404
19. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, et al. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells 2011; 29:1338-48; PMID:21732474
20. Armstrong L, Tilgner K, Saretzki G, Atkinson SP, Stojkovic M, Moreno R, et al. Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. Stem Cells 2010; 28:661-73; PMID:20073085; http://dx.doi. org/10.1002/stem.307
21. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci 2012; 1254:82-9; PMID:22548573; http://dx.doi.org/10.1111/j.1749-6632.2012.06487.x
22. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 2012; 11:596-606; PMID:23122287; http://dx.doi.org/10.1016/j.stem.2012.10.002
23. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 2013; 339:222-6; PMID:23118012; http://dx.doi.org/10.1126/science.1226603
24. Zhang J, Nuebel E, Daley GQ, Koehler CM, Teitell MA. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 2012; 11:589-95; PMID:23122286; http://dx.doi.org/10.1016/j.stem.2012.10.005
25. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011; 10:1271-86; PMID:21512313; http://dx.doi.org/10.4161/cc.10.8.15330
26. Hansson J, Rafiee MR, Reiland S, Polo JM, Gehring J, Okawa S, et al. Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep 2012; 2:1579-92; PMID:23260666; http://dx.doi.org/10. 1016/j.celrep.2012.10.014
27. Panopoulos AD, Izpisua Belmonte JC. Anaerobicizing into pluripotency. Cell Metab 2011; 14:143-4; PMID:21803281; http://dx.doi.org/10.1016/j. cmet.2011.07.003
28. Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102:4783-8; PMID:15772165; http://dx.doi.org/10.1073/pnas.0501283102
29. Powers DE, Millman JR, Huang RB, Colton CK. Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics. Biotechnol Bioeng 2008; 101:241-54; PMID:18727033; http://dx.doi.org/10.1002/ bit.21986
30. Westfall SD, Sachdev S, Das P, Hearne LB, Hannink M, Roberts RM, et al. Identification of oxygensensitive transcriptional programs in human embryonic stem cells. Stem Cells Dev 2008; 17:869-81; PMID:18811242; http://dx.doi.org/10. 1089/scd.2007.0240
31. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010; 7:150-61; PMID:20682444; http://dx.doi.org/10.1016/j. stem.2010.07.007
32. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009; 5:237-41; PMID:19716359; http://dx.doi. org/10.1016/j.stem.2009.08.001
33. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; http://dx.doi.org/10.1016/j. cell.2006.05.036
34. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009; 23:2134-9; PMID:19696146; http://dx.doi. org/10.1101/gad.1811609
35. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460:1132-5; PMID:19668191; http://dx.doi.org/10.1038/nature08235
36. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460:1140-4; PMID:19668186; http://dx.doi.org/10.1038/nature08311
37. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460:1136-9; PMID:19668188; http://dx.doi.org/10.1038/nature08290
38. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460:1149-53; PMID:19668189; http://dx.doi.org/10.1038/ nature08287
39. Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010; 7:651-5; PMID:21112560; http://dx.doi. org/10.1016/j.stem.2010.11.015
40. Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming. Biomark Med 2011; 5:715-29; PMID:22103608; http://dx.doi. org/10.2217/bmm.11.87
41. Zhang J, Khvorostov I, Hong JS, Oktay Y, Vergnes L, Nuebel E, et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J 2011; 30:4860-73; PMID:22085932; http://dx.doi.org/10.1038/ emboj.2011.401
42. Shyh-Chang N, Zheng Y, Locasale JW, Cantley LC. Human pluripotent stem cells decouple respiration from energy production. EMBO J 2011; 30:4851-2; PMID:22166995; http://dx.doi.org/10.1038/emboj.2011.436
43. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi. org/10.4161/cc.10.21.18128
44. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 2012; 11:974-89; PMID:22333578; http://dx.doi.org/10. 4161/cc.11.5.19450
45. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29:1181-9; PMID:10598751; http://dx.doi.org/10.1080/ 004982599238047
46. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002; 48:155-71; PMID:11860207; http://dx.doi. org/10.1023/A: 1013713905833
47. Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13:263-9; PMID:22436749; http://dx.doi.org/10.1038/nrm3314
48. Suhr ST, Chang EA, Tjong J, Alcasid N, Perkins GA, Goissis MD, et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One 2010; 5:e14095; PMID:21124794; http://dx.doi.org/10.1371/journal. pone.0014095
49. Zeuschner D, Mildner K, Zaehres H, Schöler HR. Induced pluripotent stem cells at nanoscale. Stem Cells Dev 2010; 19:615-20; PMID:19527182; http://dx.doi.org/10.1089/scd.2009.0159
50. Piccoli C, Ria R, Scrima R, Cela O, D'Aprile A, Boffoli D, et al. Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells. Novel evidence of the occurrence of NAD(P)H oxidase activity. J Biol Chem 2005; 280:26467-76; PMID:15883163; http://dx.doi.org/10.1074/jbc.M500047200
51. Chen CT, Shih YR, Kuo TK, Lee OK, Wei YH. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008; 26:960-8; PMID:18218821; http://dx.doi. org/10.1634/stemcells.2007-0509
52. Lonergan T, Bavister B, Brenner C. Mitochondria in stem cells. Mitochondrion 2007; 7:289-96; PMID:17588828; http://dx.doi.org/10.1016/j. mito.2007.05.002
53. Chung S, Dzeja PP, Faustino RS, Perez-Terzic C, Behfar A, Terzic A. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 2007; 4(Suppl 1):S60-7; PMID:17230217; http://dx.doi. org/10.1038/ncpcardio0766
54. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. Aging (Albany NY) 2012; 4:393-401; PMID:22713507
55. Prigione A, Adjaye J. Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. Int J Dev Biol 2010; 54:1729-41; PMID:21305470; http://dx.doi.org/10.1387/ijdb.103198ap
56. Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, et al. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell 2011; 8:695-706; PMID:21624813; http://dx.doi.org/10.1016/j. stem.2011.04.002
57. Lipchina I, Elkabetz Y, Hafner M, Sheridan R, Mihailovic A, Tuschl T, et al. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev 2011; 25:2173-86; PMID:22012620; http://dx.doi.org/10.1101/gad.17221311
58. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011; 29:443-8; PMID:21490602; http://dx.doi.org/10.1038/nbt.1862
59. Lipchina I, Studer L, Betel D. The expanding role of miR-302-367 in pluripotency and reprogramming. Cell Cycle 2012; 11:1517-23; PMID:22436490; http://dx.doi.org/10.4161/cc.19846
60. Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, et al. The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle 2013; 12:207-18; PMID:23287468; http://dx.doi.org/10.4161/cc.23352
61. Arrell DK, Terzic A. Systems proteomics for translational network medicine. Circ Cardiovasc Genet 2012; 5:478; PMID:22896016; http://dx.doi. org/10.1161/CIRCGENETICS.110.958991
62. Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, et al. Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc 2012; 7:1068-85; PMID:22576106; http://dx.doi. org/10.1038/nprot.2012.048
63. Arrell DK, Niederländer NJ, Faustino RS, Behfar A, Terzic A. Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of tumor necrosis factor alpha-primed endodermal secretome. Stem Cells 2008; 26:387-400; PMID:17991915; http://dx.doi.org/10.1634/stemcells.2007- 0599
64. Zlatkovic-Lindor J, Arrell DK, Yamada S, Nelson TJ, Terzic A. ATP-sensitive K(+) channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy. Stem Cells 2010; 28:1355-67; PMID:20572010; http://dx.doi.org/10.1002/stem.465
65. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, et al. Cardiopoietic programming of embryonic stem cells for tumorfree heart repair. J Exp Med 2007; 204:405-20; PMID:17283208; http://dx.doi.org/10.1084/ jem.20061916
66. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20:3551-67; PMID:10612281; http://dx.doi.org/10.1002/ (SICI)1522-2683(19991201)20:18<3551: :AIDELPS3551>3.0.CO;2-2
67. Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008; 24:282-4; PMID:18006545; http://dx.doi.org/10.1093/bioinformatics/btm554
68. Barabasi AL, Albert R. Emergence of scaling in random networks. Science 1999; 286:509-12; PMID:10521342; http://dx.doi.org/10.1126/science.286.5439.509
69. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabási AL. The large-scale organization of metabolic networks. Nature 2000; 407:651-4; PMID:11034217; http://dx.doi.org/10.1038/35036627t